

# THE LANCET **Neurology**

## **Supplementary webappendix**

This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Olanow CW, Kieburtz K, Per Odin P, et al, for the LCIG Horizon Study Group. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. *Lancet Neurol* 2013; published online Dec 20. [http://dx.doi.org/10.1016/S1474-4422\(13\)70293-X](http://dx.doi.org/10.1016/S1474-4422(13)70293-X).

Supplementary Figure 1: LCIG system



## Supplementary Material 1

### Site Investigator Appendix

#### *Principle Investigators*

**Germany:** Prof. Gunther Deuschl, MD (Universitaetsklinikum Schleswig-Holstein); Dirk Dressler, MD (Medizinische Hochschule Hannover); Karla Eggert, MD (Philipps-Universität Marburg); Rejko Krueger, MD (Universitaetsklinikum Tuebingen); Siegfried Muhlack, MD (Universitaetsklinikum Bochum); Alexander Storch, MD (Universitaetsklinikum Carl Gustav Carus); **New Zealand:** Prof. Timothy Anderson, MD (Christchurch Hospital); Dr. Barry Snow, MD (Auckland City Hospital); Dr. Paul L. Timmings, FRACPMD (Waikato Hospital); **United States:** James T. Boyd, MD (University of Vermont); Karen Frei, MD (Parkinson's & Movement Disorder Institute); Ramon Gil, MD (Parkinson's Disease Treatment Center of SW Florida); Mark Lew, MD (University of Southern California); Michael A. Lobatz, MD (Neurocenter); William McElveen, MD (Bradenton Research Center, Inc.); Fernando L. Pagan, MD (Georgetown University Hospital); Brad A. Racette, MD (Washington University School of Medicine); Ramon L. Rodriguez, MD (University of Florida); John T. Slevin, MD (University of Kentucky); Cheryl Waters, MD (Columbia University); William J. Weiner, MD (University of Maryland); Cindy Zadikoff, MD (Northwestern University).